Trial Profile
A Randomised, Open-Label, Proof-of-Concept, Phase II Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Nov 2021
Price :
$35
*
At a glance
- Drugs IMM 101 (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Proof of concept
- Acronyms IMAGE 1
- Sponsors Immodulon Therapeutics
- 16 Dec 2019 According to an Immodulon Therapeutics media release, data from this study were presented at the Pancreatic Cancer Symposium, on 23-24 October 2019.
- 06 Sep 2016 Results published in the British Journal of Cancer
- 06 May 2016 End date in EudraCT is closer to planned end date in NCT, I have completed the trial as NCT is not updated from long back.